147 related articles for article (PubMed ID: 11136388)
1. Product choice and haemophilia treatment in the Netherlands.
Mauser-Bunschoten EP; Roosendaal G; van den Berg HM
Haemophilia; 2001 Jan; 7(1):96-8. PubMed ID: 11136388
[TBL] [Abstract][Full Text] [Related]
2. Treatment decisions and usage of clotting factor concentrate by a cohort of Indian haemophilia patients.
Dharmarajan S; Gund P; Phadnis S; Lohade S; Lalwani A; Kar A
Haemophilia; 2012 Jan; 18(1):e27-9. PubMed ID: 21981421
[No Abstract] [Full Text] [Related]
3. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Bykov K; Bohn RL; Ewenstein BM; Seeger JD; Avorn J; Bateman BT
Thromb Haemost; 2017 Dec; 117(12):2267-2273. PubMed ID: 29212114
[TBL] [Abstract][Full Text] [Related]
4. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
[TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale.
Lock J; Raat H; Duncan N; Shapiro A; Beijlevelt M; Peters M; Tamminga RY; Leebeek FW; Moll HA; Cnossen MH
Haemophilia; 2014 Sep; 20(5):616-23. PubMed ID: 24861732
[TBL] [Abstract][Full Text] [Related]
6. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
7. Making a therapeutic choice: human versus recombinant fractions - can we do it?
Aledort LM
Haemophilia; 2001 Jan; 7 Suppl 1():1-3. PubMed ID: 11240611
[TBL] [Abstract][Full Text] [Related]
8. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system.
Calvez T; Biou M; Costagliola D; Jullien AM; Laurian Y; Rossi F; Rothschild C; Sié P;
Haemophilia; 2001 Jan; 7(1):82-8. PubMed ID: 11136385
[TBL] [Abstract][Full Text] [Related]
9. Management of difficult-to-treat inhibitor patients.
Giangrande PL; Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():52-7. PubMed ID: 20586803
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
11. Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
Hedner U
Haemophilia; 2010 Mar; 16(2):372-3. PubMed ID: 20028420
[No Abstract] [Full Text] [Related]
12. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
15. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
16. [Acquired haemophilia: From registers' data to therapeutic recommendations].
Lévesque H
Rev Med Interne; 2013 Jan; 34(1):1-3. PubMed ID: 22998977
[No Abstract] [Full Text] [Related]
17. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.
Santagostino E; Mannucci PM; Bianchi Bonomi A
Haemophilia; 2000 Jan; 6(1):1-10. PubMed ID: 10632734
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance induction: recombinant vs. human-derived product.
Berntorp E
Haemophilia; 2001 Jan; 7(1):109-13. PubMed ID: 11136391
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.
Majumdar S; Ostrenga A; Latzman RD; Payne C; Hunt Q; Morris A; Iyer R
Haemophilia; 2011 Jul; 17(4):717-8. PubMed ID: 21323798
[No Abstract] [Full Text] [Related]
20. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
